Reading EZRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EZRA free→
RELIANCE GLOBAL GROUP INC (EZRA)
NASDAQFinancialsInsurance BrokersSnapshot 2026-06-16
Watch· this week
$3.53-0.56%
Close 2026-06-16 · 1-day change
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 134% below where it trades (it looks expensive on this basis); the read is rich. Key factors to watch include the performance of sector bellwethers and any potential changes in interest rates. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NASDAQ
- Sector
- Financials
- Industry
- Insurance Brokers
- Market cap
- $1.96M
- Employees
- —
- IPO date
- 2020-10-08
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.53. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryinexpensive
$8.25consensus
Range $4.84 – $11.66
vs price: -57% below
Method agreement — · 2 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$16.97consensus
Range $16.97 – $16.97
vs price: -79% below
Method agreement — · 1 method
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Re-ratingmedium confidence
At $3.53 EZRA trades at 4× p/s — 1.5× the 3× p/s peer median. The market is re-rating it beyond its own range; our $1.49 fair value is medium-confidence here. Not investment advice.
Multiple (P/S)
4.3x
peer 2.9x · own history —
Premium
1.5x peer
Growth the price needs
134%
our forecast -11%
Our fair value
$1.49
range $1.06 – $1.93
WhyEarnings too small for P/E
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
inexpensiverich12-month view
What's priced inUnjustified
The market is pricing in roughly 134% near-term growth, well above our forecast of about -11%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Low fragilityrisk posture, not a price call
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
Historical context
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
weakOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Financials names rated weak grew net income 56% of the time over the next year (vs 59% for the rest of the cohort, n=3730).
7th pctl · Financials
Earnings quality
loss makingOver the trailing year it converted 0.57x of net income into operating cash flow.
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
Management & capital allocation
volatile30 material management or governance events in the past 24 months, led by M&A activity. Historically, Financials names rated volatile grew net income 54% of the time over the next year (vs 57% for the rest of the cohort, n=3774).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Sector context
Intermediate · WeeklySector phase: financials is in growth, with decelerating (~3.2 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: Growth by revenue growth · theme capital-markets/rates.headwind-4.4%sector vs S&P 500, 60d
via XLF
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
AI cycle regime · market-wide
2-axis classifierLong-term · 1–3 yr
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: weakProvisional
- Capital allocation
- weak
- Margin discipline
- weak
- Balance sheet
- neutral
- Post-call reaction
- weak
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-16
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$374.
How much price usually moves either way.
On a bad day, this stock has moved -$1,883.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,904.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- score change · valuation_scoresmall change
Valuation rose by 13.6 points (from 9.2 to 22.8).
- label change · valuation_labelsmall change
Valuation label changed from 'expensive' to 'inexpensive'.
No material changes since the prior snapshot.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for EZRA yet.
This sector is also watching
- Watch for revenue growth dropping below 10% across major banks
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like MRSH, AON, and AJG keep beating earnings and guiding higher, the Financials sector momentum should keep lifting EZRA and other Financials names. Worth watching these names for early signals.
Downside triggers
- If the Fed starts cutting rates from the current 3.62%, that would weigh on EZRA and other Financials names, since the sector usually outperforms when rates stay high.
- If sector bellwethers like MRSH, AON, and AJG start missing or guiding lower, the Financials tailwind helping EZRA and other Financials names could fade. Watch these names for early warning.
- If GDP growth slows materially from the current 2.6% (say, below 2%), it hits EZRA and other Financials names harder than the average stock, since the sector is growth-sensitive.
- If EZRA misses again next quarter like this past one (a big miss of -37% on the 2023-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-041mo agoItem 1.01
Entry into a Material Definitive Agreement. On April 30, 2026 (the “Closing Date”), Reliance Global Group, Inc. (the “Company”) and certain of its affiliates entered into a series of definitive agreements (collectively, the “Transaction Documents”) in connection with the formation of LifeSci Global Group LLC, a Delaware limited liability company (“LGG”), and the consummation by LGG of an initial investment in Innervate Radiopharmaceuticals LLC, a Delaware limited liability company (“Innervate…
M&A activitypositive
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+2.1 vs last weeklatest as of 2026-06-17
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.